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Abstract
Background: Community-acquired pneumonia (CAP) remains a leading cause of death worldwide, and
hypoalbuminemia is associated with worse outcomes. However, it remains uncertain whether albumin administration
could have any beneficial effects. We aim to assess whether the administration of albumin in hypoalbuminemic patients
with CAP increases the proportion of clinically stable patients at day 5 compared with the standard of care alone.
Methods: This is a trial protocol for a superiority, non-blinded, multicenter, randomized, phase 3, interventional controlled
clinical trial. The primary endpoint will be the proportion of clinical stable patients at day 5 (intention to treat), defined as
those with stable vital signs for at least 24 h. The secondary endpoints will be time to clinical stability, duration of
intravenous and total antibiotic treatment, length of hospital stay, intensive care unit admission, duration of mechanical
ventilation and vasopressor treatment, adverse events, readmission within 30 days, and all-cause mortality. The trial has
been approved by the Spanish Medicines and Healthcare Products Regulatory Agency. The investigators commit to
publish the data in peer-reviewed journals within a year of the study completion date. Subjects will be recruited from
three Spanish hospitals over a planned enrolment period of 2 years. A follow-up visit will be performed 1month after
discharge. We have estimated the need for a sample size of 360 patients at a two-sided 5% alpha-level with a power of
80% based on intention to treat. Eligible participants must be hospitalized, hypoalbuminemic (≤ 30 g/L), non-
immunosuppressed, adults, and diagnosed with CAP. They will be randomly assigned (1:1) to receive standard care
plus albumin (20 g in 100mL) every 12 h for 4 days or standard care alone.
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Discussion: If this randomized trial confirms the hypothesis, it should lead to a change in current clinical practice for
the management of hypoalbuminemic patients with CAP.
Trial registration: European Clinical Trials Database (EudraCT) 2018-003117-18. Registered on 12 April 2019.
ClinicalTrials.gov NCT04071041. Registered on 27 August 2019
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Background
Community-acquired pneumonia (CAP) is an important
public health problem [1]. This is underlined by an an-
nual incidence of approximately 6.49 per 1000 inhabi-
tants and a 10-fold rise in certain subgroups, such as the
elderly and patients with chronic obstructive pulmonary
disease [2]. Lower respiratory tract infection, and CAP
in particular, is a significant cause of morbidity and mor-
tality and remains a leading cause of death in high-
income countries [3, 4].
Despite a decrease in short-term mortality among
adult patients hospitalized with CAP over recent years,
about 10% of these patients continue to die [2, 5, 6], with
this figure rising to 28% in patients admitted to intensive
care units (ICU), even when antibiotic treatment is ad-
equate [7]. CAP has a significantly higher long-term
mortality rate than many other conditions [8], occurring
in nearly 1 in 3 adults 1 year after hospitalization [2].
CAP may also trigger acute cardiac events, further increas-
ing morbidity, length of hospitalization, and mortality [9,
10]. Unsurprisingly, therefore, the economic burden of
CAP is high, with an estimated yearly cost of 10.1 billion
euros in Europe [11] and 13.4 billion dollars in the USA
[12]. Inpatient care accounts for most of this cost, with
length of stay, which is linked to a longer time to clinical
stability, being the most significant factor. Longer stays also
increase the risks of complications, such as phlebitis, ulcers,
adverse drug reactions, and nosocomial infection [13].
The progress of patients hospitalized with CAP is crucial
in the first days of therapy. In fact, once clinical stability is
achieved, the course of infection is usually favorable [14].
Several studies have demonstrated that an inadequate in-
flammatory response is a major cause of early treatment fail-
ure and mortality [15–17]. Hypoalbuminemia also occurs
often and is associated with poor outcomes in acutely ill
patients, but it is unclear if this association is causal [18, 19].
A meta-analysis of 90 cohorts and 9 prospective controlled
studies indicated that hypoalbuminemia was an independent
predictor of poor outcome [18]. Hypoalbuminemia at
admission is associated with higher mortality in se-
vere sepsis [19] and with worse outcomes in patients
with CAP [20–23], including a prolonged time to
clinical stability and a longer hospitalization stay [22].
In humans, albumin accounts for about 50% of all
plasma protein, while its molecular structure and
concentration make it responsible for about 80% of the
intravascular oncotic pressure [24]. Albumin metabolism
in hospitalized patients is complex, and the pathophysi-
ology underlying the relationship between plasmatic
concentrations and ill-health is poorly understood. We
know that stress and infection are associated with hypo-
albuminemia, with an increase in albumin clearance, ra-
ther than decreased albumin synthesis, being dominant
[25, 26]. In fact, a higher rate of albumin synthesis is
typically observed in patients in ICU [27] and with acute
inflammatory abdominal disease [28], and in healthy vol-
unteers within 3 h after endotoxin administration [29].
It is now well accepted that, besides a role in maintain-
ing colloidal osmotic pressure, albumin has secondary
functions that are critical to normalizing many of the in-
flammatory pathways involved in sepsis [30]. Albumin
transports many compounds and is responsible for most
drug-protein binding, including antibiotics. Hypoalbumin-
emia can therefore lead to significant pharmacokinetic
variation, such as an increased volume of distribution and
an increased clearance of antibiotics [31]. Albumin also
exerts specific antioxidant functions due to its multiple
ligand-binding capacities, with two thirds of extracellular
albumin existing in its reduced form. The reduced
cysteine-34 (Cys34) residue accounts for 80% of plasma
thiols, allowing albumin to trap reactive oxygen species,
nitric oxygen, other reactive nitrogen species, and prosta-
glandins [32]. Moreover, albumin can bind several bacter-
ial products [33]. In an endotoxin animal model, human
albumin treatment was shown to have a dose-dependent
protective effect on endothelial dysfunction through the
inhibition of inflammatory and oxidative stress pathways
[34]. Commercially available albumins differed in some of
their antioxidant properties, primarily due to different
levels of free Cys34 [35]. Our knowledge of the immuno-
modulatory effects of albumin is derived from in vitro and
animal studies. Albumin enhances the ability of antigen-
presenting cells to trigger T cell activation by increasing
major histocompatibility complex II and human leukocyte
antigen-DR expressions [36]. In fact, by binding prosta-
glandin E2, albumin was able to restore immune compe-
tence in patients with decompensated end-stage cirrhosis
[37]. Two recent clinical trials demonstrated improved
survival and a reduction in spontaneous bacterial periton-
itis and other bacterial infections in cirrhotic patients with
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ascites [38, 39]. In endotoxemic rats, albumin resuscitation
improved ventricular dysfunction by improving myocar-
dial hypoxia and decreasing hypoxia-inducible factor
(HIF)-1α expression [40].
To date, studies assessing albumin administration have
focused on heterogeneous populations of septic and crit-
ically ill patients. A large randomized clinical trial evalu-
ating the effect of volume replacement with human
albumin versus crystalloid in 7000 critically patients
failed to show a survival benefit, but decreased mortality
was shown in a predefined subanalysis of patients with
severe sepsis [41]. Consequently, the randomized con-
trolled ALBIOS trial studied the impact of albumin ad-
ministration in severe sepsis and septic shock, and
although this also showed no mortality benefit, a post hoc
subanalysis suggested that there was a lower 90-day mor-
tality in the albumin group with septic shock [42]. Several
systematic meta-analyses of albumin therapy in sepsis or
septic shock have shown trends toward 90-day reductions
in mortality associated with septic shock [43, 44], espe-
cially when administered within 6 h [45]. Other studies
did not find any benefit [46–48]. However, it should be
noted that these included different populations, compara-
tors, and durations. This evidence led to the weak recom-
mendation and low quality of evidence for using albumin
in addition to crystalloids in the initial resuscitation of
sepsis and septic shock in the surviving sepsis guidelines
[49]. Although two new trials, ARISS (NCT03869385) and
ALBIOSS-BAL (NCT03654001), seek to assess the impact
of albumin administration in septic shock, no randomized
trial has either been conducted or planned to analyze the
effect of albumin treatment in patients with CAP.
We designed the current randomized multicenter trial
to assess whether standard care plus albumin therapy
will increase the proportion of clinically stable patients
at day 5 of admission compared to standard care alone
in patients with CAP and hypoalbuminemia.
Design
Study design and setting
This publicly funded academic study will be a non-
blinded, multicenter, randomized, parallel, phase 3,
interventional controlled clinical trial into the superiority
of albumin plus standard therapy over standard therapy
alone. The trial is sponsored by Dr. Jordi Carratalà—
Hospital de Bellvitge—and began on November 14,
2019, and will run to November 2021. Patients will be
recruited in three hospitals in Barcelona, Spain (Bellvitge
University Hospital, SCIAS Hospital of Barcelona, and
the Hospital Sant-Camil-Consorcio Sanitario Garraf). All
items from the WHO Trial Registration Data Set have
been registered at the publicly accessible databases Clinical-
Trials.gov (NCT04071041) and European Clinical Trials
Database (EudraCT 2018-003117-18). Informed consent
will be obtained from all patients or their next of kin by the
principal and subinvestigators.
Study population
All hospitalized patients with CAP and hypoalbumin-
emia at presentation will be assessed for eligibility within
24 h of hospital admission.
The inclusion criteria are as follows:
 Age ≥ 18 years
 Diagnosis of CAP (Table 1)
 Serum albumin concentration ≤ 30 g/L at
presentation
The exclusion criteria are as follows:
 Pregnancy or lactation
 Immunosuppression, such as chemotherapy or
radiotherapy (< 90 days), immunosuppressive
drugs, corticosteroids within 2 weeks of enrolment
(≥ 15 mg/day of prednisone or equivalent), HIV-
positive (CD4 count < 200), and solid organ or
hematopoietic cell transplant recipients
 Severe clinical status with expected survival ≤ 24 h
 Congestive heart failure (New York Heart
Association classes 3 or 4)
 Any contraindication for albumin administration,
such as hypersensitivity to albumin
 Clinical conditions with an indication for albumin
(e.g., hepatic cirrhosis with ascites, malabsorption
syndrome, or nephrotic syndrome)
 Absence or impossibility of obtaining informed
consent from patient or next of kin
 Patient already included in another clinical trial for a
treatment method
Patient and public involvement
When designing the study, our first priority was patient
well-being. However, we have not included either pa-
tients or the public in the design, recruitment, or con-
duct of the study. Participants can request information
Table 1 Definition of community-acquired pneumonia
• Chest radiography consistent with community-acquired pneumonia
• The presence of ≥ 2 following pre-specified clinical criteria:
- Fever or hypothermia
- Cough
- Purulent sputum
- High white blood cell count
- Dyspnea
- Pleuritic chest pain
- Signs consistent with pneumonia on chest auscultation
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about the study results through the principal investigator
at any time.
Randomization and allocation concealment
The Biostatistics Unit at IDIBELL will generate a cen-
tralized pre-specified block randomization list. The pro-
gram will assign patients on a 1:1 basis to either
standard care plus albumin or standard care alone. The
block size will be ten, and participants will be stratified
by center. The allocation list will be stored at the Bio-
statistics Unit.
Intervention
Patients in the intervention group will be randomly allo-
cated to receive standard care plus albumin 20% (20 g in
100 mL; Albutein Instituto Grifols, S.A. Can Guasch 2,
Parets del Vallès, 08015 Barcelona, Spain) intravenously
every 12 h for 4 days or until death, discharge, or clinical
stability, whichever occurs first. Patients enrolled in the
study will not require extended hospitalization or add-
itional follow-up. Patients will receive empirical anti-
biotic therapy according to the relevant guidelines, as
soon as CAP is confirmed. All microbiological assess-
ments and additional treatments (e.g., oxygen, broncho-
dilators, corticosteroids, analgesics, vasoactive agents,
fluid resuscitation, and mechanical ventilation) will be at
the discretion of the treating physicians in both groups.
The time of discharge and the duration of antibiotic
therapy will not be determined by the study investiga-
tors, but by the treating team.
Primary endpoint
The primary endpoint will be the proportion of clinically
stable patients at day 5 of hospital admission. Clinical
stability will be defined as previously described by Halm
et al. as achieving normal oral intake, normal mental sta-
tus (or usual level of function), and stable vital signs for
at least 24 h (Table 2).
Secondary endpoints
The following secondary endpoints will be assessed:
 Time to clinical stability (days) measured from
hospital admission
 Duration of intravenous and total antibiotic
treatment (days)
 Length of hospital stay (days)
 ICU admission (time to discharge and durations of
treatment with vasopressors and mechanical
ventilation)
 Nosocomial infection during hospitalization
 Adverse events
 Hospital readmission within 30 days after discharge
 All-cause mortality at 5 and 30 days, as well as 30
days of discharge
Stop treatment criteria
Comorbidities of CAP will not be considered sufficient
to withdraw a patient from the study. However, the fol-
lowing stop criteria will be applied:
 Any unexpected serious adverse event between day
0 and day 5
 Clinical judgment of an attending physician or study
investigator
 Voluntary withdrawal of consent
 Serious protocol violation
 Loss to follow-up
 Pregnancy during the study
 Congestive heart failure (New York Heart
Association classes 3 or 4).
Follow-up and data collection
All included patients will be daily assessed by a member
of the investigating team until discharge or death. Con-
sistent with routine clinical practice, a follow-up visit
will be arranged for all participating patients 1 month
after discharge. For patients who do not attend follow-
up or in case of mobility restrictions in response to the
COVID-19 pandemic, a structured telephone interview
will be done to assess outcomes. A summary of the trial
visit schedule and associated assessments is displayed in
Fig. 1. Baseline data will include the following: date and
time of randomization, demographic data, medical history
items, relevant comorbidities, clinical features, causative
organisms, antibiotic susceptibilities, antibiotic treatments,
other medications, biochemical and microbiological ana-
lysis, and variables for the pneumonia severity index (PSI).
Albumin concentration will be determined on days 0 and
5. Medication dosages will be recorded, and adverse
events will be monitored appropriately throughout the
study. In-hospital complications and cardiac events will be
assessed. Any additional diagnostic testing in either group
will be at the discretion of the treating physician. All data
will be recorded on a secure web application used for
building and managing online databases (REDCap). The
sponsor and investigator will have access to the final trial
Table 2 Definition of clinical stability (Halm et al. 1998) [14]
• Temperature ≤ 37.8 °C without antipyretic agents
• Heart rate ≤ 100 per minute
• Spontaneous respiratory rate ≤ 24 per minute
• Systolic blood pressure ≥ 90 mmHg without vasopressor support
• Adequate oxygenation on room air (PaO2≥ 60mmHg or pulse
oximetry ≥ 90%)a
aFor patients with chronic hypoxemia or chronic oxygen therapy, PaO2, or
pulse oximetry measurement, must be back to baseline
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dataset. Authorized staff may examine the records for
quality assurance and audit purposes.
Statistical analysis plan
Sample size and power calculations
This study is designed to show the superiority of the
intervention group (standard care plus albumin) at a
two-sided 5% alpha-level with a power of 80% based on
intention to treat. According to our own experience, the
prevalence of hypoalbuminemia is 37% in patients pre-
senting with CAP, with a predicted mortality rate of 10%
[22]. We predicted that 58% of participants would be
clinically stable at day 5 in the standard care group, with
a difference of 15% between the two treatment arms.
Given a possible deviation of 10% from the protocol, we
will need a sample of 360 patients (180 per arm) to
achieve a statistical power of 80% and a 5% significance
level (two-sided). We aim to screen 900 patients.
Type of analysis
We will use IBM SPSS version 21.0 (IBM Corp.,
Armonk, NY, USA) and R for Windows (R Foundation
for Statistical Computing, http://www.r-project.org) for
data analysis.
The primary analysis population is the full data set
that includes the intention to treat population (all ran-
domized patients). Every effort will be made to
minimize the number of losses to follow-up. A
secondary analysis will be conducted in a per-protocol
population, excluding patients not treated according to
the protocol. For sensitivity analysis, the primary ana-
lysis will then be repeated in the per-protocol popula-
tion and by multivariable t test model (adjusted for
potentially important confounders, such as age and PSI
score).
We also plan to investigate whether the treatment ef-
fect varies between different CAP severities, between pa-
tients with and without chronic cardiac disease, and
between patients with and without bacteremia. We will
conduct the pre-specified subgroup analyses by includ-
ing appropriate interaction terms in the multivariable t
test. Complete case analyses will be used for secondary
endpoints, for which we will calculate both unadjusted
and adjusted estimates of the effect size and correspond-
ing 95% confidence intervals by linear, logistic, or Cox
proportional hazards regression.
The trial will be open, but the statistical analyst will be
blind to the intervention and control group allocation.
Interim analysis
To ensure sufficient statistical power, the sample size
will be recalculated once half of the initial study popula-
tion (180 patients) has been recruited. The necessity to
increase the initial estimated sample size will be consid-
ered based on any variabilities encountered.
Fig. 1 Participant timeline
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Monitoring
Data will be monitored by a Data Monitoring Commit-
tee from the IDIBELL Clinical Research and Clinical Tri-
als Unit. This committee is co-funded by the European
Union and the Instituto de Salud Carlos III, Spanish
Ministry of Science, Innovation and Universities, and it
is independent of the sponsor.
Adverse event reporting
An independent safety monitoring committee will review
safety data. Any adverse event and its possible relation-
ship to the study drug will be noted in patients’ clinical
records. All severe adverse events (including death), and
any related adverse events, will be recorded on the elec-
tronic case report form according to the Common Termin-
ology Criteria for Adverse Events. An adverse event will be
considered related to the study medication whenever a
temporal relationship suggests a reasonable causal connec-
tion and/or the occurrence cannot be better explained by
factors like the clinical status or another therapeutic inter-
vention. The investigators will declare any serious adverse
events to the sponsor within 24 h, and we will present a
yearly security update report to the local regulatory agency
consistent with the recommendations of the International
Council for Harmonisation (ICH E2F).
Indemnities
This study is classified as a low-intervention trial. Ac-
cording to Spanish law (Real Decreto 1090/2015), all
damages incurred should be covered by the civil liability
insurance of the participating study centers. An ad hoc
insurance for the SCIAS Hospital of Barcelona (a private
institution) has been taken out.
Dissemination
The results will be presented at national and inter-
national meetings. The investigators commit to publish
the data in peer-reviewed journals within a year of the
study completion date. The datasets generated during
the study will be available from the corresponding au-
thor on reasonable request.
Protocol amendments
Relevant protocol modifications will not become effective
until approved by the relevant authorities and the Drug
Research Ethics Committee. Exceptions are changes to
protect patients from imminent harms or exclusively con-
cerning logistic and administrative aspects.
A protocol amendment adding pneumonia caused by
SARS-CoV-2 to the exclusion criteria has been submit-
ted and is currently pending decision from the relevant
authorities and the Drug Research Ethics Committee.
Discussion
Hypoalbuminemia is associated with worse outcomes in
both sepsis and CAP [19–23]. To date, studies evaluating
the efficacy of albumin therapy have been performed in
heterogeneous populations of critically ill and septic
patients. As such, they have rendered conflicting results
[41, 42], although some have indicated clear benefits,
notably in post hoc subgroup analyses [43]. We hypothesize
that albumin administration in hypoalbuminemic patients
with CAP could improve both the immune response and
degree of organ dysfunction, thereby reducing the length of
hospitalization and the time to clinical stability. This open-
label randomized trial is designed to test this hypothesis,
and it is expected that the results will determine if the
addition of albumin therapy to standard care improves clin-
ical outcomes. Even if the results are negative, we can con-
firm that there is no justification to change current clinical
practice. However, if our hypothesis is proven, our study re-
sults could lead to a major change in practice.
Trial status
The present manuscript describes the current authorized
protocol at submission: version 1.1, 28 March 2019. The
first patient was recruited on 14 November 2019, and
enrollment is planned to run to November 2021. Re-
cruitment was temporally halted from 14 March 2020 to
7 June 2020 due to the SARS-CoV-2 pandemic.
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